Pulmonary Function Testing Systems Market Size & Share 2026-2035

Pulmonary Function Testing Systems Market Size

The pulmonary function testing systems market was valued at USD 3.1 billion in 2025 and is projected to increase from USD 3.2 billion in 2026 to USD 5.9 billion by 2035, expanding at a CAGR of 6.9%.

Pulmonary function testing systems include handheld and tabletop instruments, interpretation software, and clinically integral accessories used to measure airflow, lung volumes, and gas exchange. Their role extends from initial diagnosis and treatment monitoring to pre-operative assessment, occupational surveillance, and longitudinal management of chronic respiratory disease. Spirometry is central to COPD diagnosis, while full PFT protocols add lung-volume and diffusion measurements when spirometry alone cannot resolve restrictive, obstructive, or mixed physiology. ^{[1]World Health Organization, Chronic obstructive pulmonary disease (COPD), 2024, who.int}

The addressable need is anchored in chronic respiratory disease rather than discretionary testing. COPD caused 3.5 million deaths in 2021 and remains the third leading cause of death worldwide; WHO identifies spirometry as necessary to confirm diagnosis, yet notes that its limited availability in low- and middle-income countries contributes to missed cases. A global modelling study estimated that 391.9 million people aged 30-79 years were living with COPD in 2019 under the GOLD spirometric definition. Asthma affected an estimated 262 million people and caused 455,000 deaths in 2019, according to WHO. These conditions create recurring testing demand because clinical management depends on objective measurement rather than symptoms alone.

The replacement cycle is also becoming more clinically consequential. The ERS/ATS technical standard for routine lung-function interpretation formalized z-score-based limits of normal, Global Lung Function Initiative reference equations, and updated bronchodilator-response interpretation. ^{[2]European Respiratory Journal, ERS/ATS technical standard on interpretive strategies for routine lung function tests, July 2022, publications.ersnet.org} Systems that cannot support current reference equations, quality-control workflows, or reporting conventions face a weaker position in institutional procurement, particularly where high test volumes make manual interpretation burdensome.

The 6.9% forecast CAGR is therefore better understood as a shift in the location and workflow of testing rather than a simple increase in respiratory disease prevalence. Standards-driven software upgrades preserve demand in established laboratories, while portable hardware, cloud connectivity, and quality-assurance tools broaden the number of sites capable of producing clinically usable tests. The higher 7.4% CAGR projected for handheld devices reflects this change in delivery model.

Key Drivers

Increase in prevalence of chronic respiratory diseases

COPD, asthma, pulmonary fibrosis, and other chronic respiratory conditions support PFT demand because diagnosis and treatment adjustment require quantifiable measures of airflow and gas exchange. COPD is especially important because diagnosis must be confirmed by spirometry, creating a direct link between case finding and equipment availability. The unmet need is concentrated in markets where disease burden is substantial but access to standardized testing remains uneven.

China illustrates the scale of this conversion opportunity. Respiratory-disease policy has been incorporated into the Healthy China 2030 agenda, while primary-care infrastructure has expanded materially over the past decade. As lung-function screening moves into a larger number of primary-care settings, demand shifts toward systems that can produce repeatable tests without requiring a dedicated laboratory at every site.

Technological advancements

Hardware and software improvements are widening the range of settings in which clinically useful spirometry can be performed. ndd Medical Technologies uses ultrasound-based TrueFlow measurement in its EasyOne portfolio and positions the technology as calibration-free, reducing a practical barrier to deployment in distributed clinical and occupational-health environments. ^{[3]ndd Medical Technologies, Products, nddmed.com} GANSHORN similarly applies ultrasound flow measurement across its pulmonary diagnostic systems, including its SpiroScout and PowerCube platforms.

Interpretation software has become a more meaningful procurement differentiator as PFT standards have become more complex. ArtiQ obtained ISO 13485 certification and CE marking under the EU MDR for its AI-powered PFT interpretation solution in January 2021. Its integration into Vyaire Medical's SentrySuite workflow is intended to support structured interpretation across spirometry, diffusion testing, lung volumes, and airway resistance. The value proposition is not automation for its own sake: it is the reduction of variability in high-volume workflows while maintaining alignment with updated clinical interpretation standards.

Connectivity further changes the economics of distributed testing. EasyOne Sky combines cloud connectivity, quality-management functions, and integration options for clinical information systems. Such capabilities are relevant where providers operate multiple sites or need to oversee home- or community-based tests without losing visibility over test quality.

Favourable government initiatives

Public-health programs influence PFT demand when they create funded pathways for respiratory case finding, surveillance, or chronic-disease management. The U.S. National Heart, Lung, and Blood Institute's COPD National Action Plan established a federal framework focused on awareness, care quality, research, and policy translation. ^{[4]National Heart, Lung, and Blood Institute, COPD National Action Plan, May 2017, nhlbi.nih.gov} The CDC's National Asthma Control Program supports state, territorial, and local programs that implement asthma surveillance and evidence-based interventions.

At the international level, WHO's chronic respiratory disease program and the Global Alliance against Chronic Respiratory Diseases promote stronger prevention and management capacity, including integration of respiratory care within health systems. These initiatives do not guarantee device purchases, but they can shape clinical protocols, workforce priorities, and public procurement criteria. In China, the combination of chronic-respiratory-disease policy and primary-care expansion gives portable spirometry a clearer institutional route to adoption than a model dependent solely on tertiary-hospital capital expenditure.

Key Restraints

Stringent regulatory framework

Pulmonary diagnostic systems must navigate medical-device requirements before market entry and throughout their commercial life. In the U.S., diagnostic spirometers are classified under 21 CFR 868.1840 and are generally associated with product code BZG. The 510(k) pathway requires manufacturers to establish substantial equivalence to a predicate device, which makes regulatory documentation, verification, and software validation material considerations in product-launch timing.

European compliance has also become more demanding under Regulation (EU) 2017/745, which has applied since May 2021. For manufacturers of Class IIa systems and clinical software, the burden extends beyond initial conformity assessment to technical documentation, post-market surveillance, and quality-system maintenance. This friction disproportionately affects smaller specialist suppliers because regulatory costs must be absorbed across narrower product portfolios and lower unit volumes.

High cost associated with pulmonary function testing devices

Cost is not confined to the purchase price of a system. Comprehensive laboratory configurations may require dedicated rooms, installation work, staff training, preventive maintenance, calibration procedures, consumables, and integration with hospital information systems. These requirements make body plethysmography, diffusion testing, and cardiopulmonary exercise testing more difficult to deploy in small facilities than basic spirometry.

The resulting constraint is most consequential in markets with limited capital budgets and weak technical-service coverage. WHO's observation that spirometry is frequently unavailable in lower-resource settings indicates that clinical need and purchasing capacity can diverge sharply. A lower-cost handheld device can reduce the initial hurdle, but it does not eliminate the need for operator training, quality assurance, referral pathways, and reimbursement. Suppliers that address only device affordability may therefore struggle to convert latent demand into sustained utilization.

This creates a strategic split between high-specification laboratory systems and portable platforms. Tabletop providers retain an advantage where lung-volume, diffusion, and exercise testing are required, but handheld suppliers can capture demand that would otherwise remain unserved because a full laboratory is economically impractical. The growth outlook consequently depends on whether manufacturers can pair simplified hardware with credible quality control, interpretation support, and service coverage.

Pulmonary Function Testing Systems Market Segment Analysis

By Product

Handheld systems generated USD 1.8 billion in 2025 and are projected to exceed USD 3.6 billion by 2035 at a CAGR of 7.4%. Their growth is supported by primary-care testing, occupational-health screening, and supervised homecare use cases where portability and lower setup requirements matter more than the breadth of a laboratory test menu. Calibration-free ultrasound systems and guided testing interfaces can reduce operating complexity, provided the device is used within an appropriate clinical quality-assurance process.

Tabletop systems were valued at USD 1.2 billion in 2025 and are expected to reach USD 2.2 billion by 2035. They remain necessary for comprehensive testing because body plethysmography, advanced diffusion assessment, and integrated cardiopulmonary exercise testing require capabilities unavailable in basic handheld configurations. COSMED's Quark PFT platform, Geratherm Respiratory's product range, GANSHORN's PowerCube series, and MGC Diagnostics' laboratory systems illustrate the multi-modality configurations used in specialist settings. ^{[5]COSMED, Pulmonary function test systems, cosmed.com}

By Test Type

Spirometry was the largest test type, valued at USD 1.4 billion in 2025, and is projected to grow at a CAGR of 7.2%. It provides FEV1, FVC, FEV1/FVC ratio, and flow-volume-loop measurements used for diagnosis and monitoring of obstructive disease. The ERS/ATS interpretive standard has increased the importance of software that applies current reference equations and lower-limit-of-normal methodology consistently.

Exercise stress testing is expected to grow from USD 576.1 million in 2025 to USD 1.2 billion by 2035 at a CAGR of 7.8%, the highest among defined test types. This segment benefits from its use in assessment of exertional symptoms and cardiopulmonary functional limitation. Its equipment intensity favors hospital and specialty-center procurement, where integration of respiratory gas analysis and cardiovascular monitoring can raise system value.

Lung-volume testing is projected to increase from USD 406.4 million in 2025 to USD 696.3 million by 2035. It remains clinically important because reduced FVC alone does not establish restriction; total lung capacity is required to confirm restrictive impairment. High-altitude simulation testing is forecast to grow from USD 285.2 million to USD 535.6 million over the same period, serving a narrower but defined need in aviation and specialist respiratory medicine. Gas-diffusion testing is expected to rise from USD 223.4 million to USD 366.4 million by 2035, supporting evaluation of alveolar-capillary gas transfer in disorders such as emphysema and interstitial lung disease.

By Application

COPD accounted for 40.1% of market revenue in 2025. Its position reflects the centrality of spirometry to diagnosis and the recurring need to reassess lung function as treatment, exacerbation history, and disease severity change. The large global COPD population creates a durable utilization base, although realized equipment demand remains dependent on testing access and provider capacity.

The asthma segment was valued at USD 791.7 million in 2025 and is projected to reach USD 1.4 billion by 2035 at a CAGR of 6.1%. Objective lung-function measurement supports diagnosis, bronchodilator assessment, and longer-term disease monitoring. The segment is particularly compatible with validated portable spirometry because many care episodes occur outside specialist laboratories.

Chronic shortness of breath generated USD 428.5 million in 2025 and is expected to reach USD 739.2 million by 2035. This application encompasses diagnostic workups where PFTs help distinguish respiratory impairment from cardiac, neuromuscular, or non-pulmonary contributors to dyspnea. Pulmonary fibrosis is projected to grow from USD 374.9 million in 2025 to USD 796.4 million by 2035, supported by the need for serial FVC and diffusion-capacity assessment in specialist disease monitoring.

By End Use

Hospitals and clinics were the leading end-use segment in 2025 and are projected to reach USD 2.6 billion by 2035. Their position reflects the concentration of high-acuity respiratory care, specialist staffing, and comprehensive testing requirements. These customers also value interoperability, service agreements, regulatory documentation, and the ability to combine multiple test modalities within one workflow.

Diagnostic centers generated USD 873.8 million in 2025 and are projected to reach USD 1.6 billion by 2035 at a CAGR of 6.3%. Their purchasing decisions are shaped by throughput, repeatability, workflow integration, and the ability to operate multiple test types efficiently. Homecare settings are expected to expand from USD 575.4 million in 2025 to USD 1.2 billion by 2035. Remote lung-function tools, including handheld spirometers and connected monitoring solutions, can support data collection beyond conventional facilities, but reliable home testing requires training, supervision, and quality-control processes. ^{[6]National Library of Medicine, Innovations in lung function monitoring, 2025, pmc.ncbi.nlm.nih.gov}

The most consequential divergence is between simple measurement and clinically actionable measurement. Suppliers that combine portable hardware with guided maneuvers, remote quality oversight, and interoperable reporting can increase the usefulness of community-based testing. At the other end of the market, suppliers with integrated CPET and complete PFT platforms are better positioned to benefit from the faster growth projected for exercise stress testing and from the complex monitoring requirements associated with pulmonary fibrosis.

Pulmonary Function Testing Systems Market Regional Analysis

North America

accounted for 47.6% of the global market in 2025. The U.S. market was valued at USD 1.4 billion in 2025 and is projected to grow at a CAGR of 5.8% through 2035. Its lower growth rate relative to the global market is consistent with a mature installed base, where demand is more dependent on replacement, software modernization, and care-setting expansion than on first-time deployment.

U.S. demand is supported by an established clinical and reimbursement environment for pulmonary diagnostic procedures and by federal respiratory-health programs. The NHLBI COPD National Action Plan and CDC asthma-control initiatives reinforce the importance of diagnosis, surveillance, and evidence-based management in public-health systems. Procurement in hospitals and large networks favors suppliers that can provide broad product portfolios, integration capabilities, and service support.

Canada

Canada's provincial health insurance frameworks cover spirometry as a reimbursed respiratory diagnostic service, sustaining stable procurement through regional health authority tenders. The market aligns with U.S. trends in technology adoption at a proportionally smaller scale.

Europe

Europe was valued at USD 687.9 million in 2025. The region combines mature respiratory-care systems with a dense concentration of specialist suppliers, including COSMED, Geratherm Respiratory, GANSHORN SCHILLER GROUP, ndd Medical Technologies, and Vitalograph. This supplier base supports product development and clinical familiarity, but EU MDR compliance raises the importance of documentation, post-market evidence, and reliable distributor support. ^{[7]European Medicines Agency, Medical devices, ema.europa.eu}

Germany

Germany is an important market for complete laboratory systems and networked diagnostic platforms. GANSHORN SCHILLER GROUP's history in German pulmonary function diagnostics, combined with its integration into SCHILLER's cardiodiagnostics distribution network, positions it effectively within German hospital procurement. Geratherm Respiratory's BLUE CHERRY networked software platform addresses the preference for scalable, integrated diagnostic data management.

United Kingdom

The UK's established respiratory-care pathways sustain spirometry use across primary and specialist care. Vitalograph's operations and ndd Medical Technologies' distribution relationships both serve this market effectively.

France

France's reimbursement framework covers respiratory function testing within the general social security system, supporting stable spirometry utilization across hospital and specialist outpatient settings.

Spain

Spain has expanded hospital-based PFT capacity through EU structural fund-supported health infrastructure programs, with rising adoption of advanced diagnostic systems.

Italy

Italy similarly benefits from EU health system investment in chronic disease management infrastructure, with spirometry reimbursed under national health insurance frameworks.

Netherlands

The Netherlands, as a strategic market for Philips' health technology operations, supports demand for respiratory sensing and diagnostic products within integrated hospital and outpatient care programs.

Asia Pacific

Asia Pacific is projected to record the highest regional CAGR at 8.8% during 2026-2035. The growth profile reflects a large untreated diagnostic need, healthcare-facility expansion, and rising demand for systems that can be deployed outside tertiary hospitals. China's policy focus on chronic respiratory disease and the expansion of primary-care institutions create an addressable market for entry-level and mid-range spirometry, particularly where testing capability is incorporated into broader chronic-disease management. ^{[8]Respiratory Research, Chronic obstructive pulmonary disease in China: a review of epidemiology and management, 2026, link.springer.com}

China

China's policy focus on chronic respiratory disease and the expansion of primary-care institutions create an addressable market for entry-level and mid-range spirometry. GANSHORN identifies China as one of its strongest markets alongside Europe, reflecting established commercial traction for European-origin PFT technology in Chinese hospital procurement.

Japan

Japan contributes both demand and manufacturing capability through companies such as CHEST M.I., FUKUDA SANGYO, and MINATO MEDICAL SCIENCE. Its aging population sustains per-capita respiratory diagnostic demand at rates that outpace overall population growth.

India

India offers substantial longer-term potential, but cost, training, service availability, and uneven access to testing infrastructure remain limiting factors in the near term.

South Korea

South Korea's high healthcare technology adoption rates and consistent hospital construction activity support PFT device replacement and upgrade cycles.

Latin America

Latin America was valued at USD 177.5 million in 2025. Brazil and Mexico provide the principal opportunities because of their larger healthcare markets and private-sector diagnostic capacity. However, imported-device dependence, currency exposure, and constrained public capital budgets can delay purchases of full PFT laboratories.

The regional opportunity is therefore not a single export market. China requires scalable primary-care deployment; Japan and South Korea reward technical capability and local-market alignment; India and parts of Latin America require lower deployment costs and dependable service networks; GCC markets can support high-specification hospital systems. Manufacturers that treat these markets as variations of the same hospital tender are likely to underperform suppliers that align product configuration, technical support, and channel strategy with local care delivery.

Pulmonary Function Testing Systems Market Share & Competitive Landscape

The market remains fragmented, with the top five companies-Baxter, COSMED, ndd Medical Technologies, PHILIPS, and Vyaire MEDICAL-holding approximately 29% collectively in 2025. Competitive advantage depends on the supplier's position across two distinct requirements: comprehensive clinical testing in specialist laboratories and scalable spirometry deployment in distributed care settings.

Baxter

Baxter offers respiratory-therapy systems, including The Vest airway-clearance system, Synclara cough-assist system, Volara therapy system, and Monarch portable airway-clearance system. ^{[9]Baxter, Respiratory therapy devices, pro.baxter.com} Its respiratory portfolio is weighted toward airway-clearance and respiratory-support solutions rather than complete diagnostic PFT laboratory platforms.

CHEST M.I.

CHEST M.I. is a Japanese medical-instrument manufacturer with pulmonary-function-testing offerings including the C-8900 PFT system, HI-801 multifunction spirometer, CHESTGRAPH HI-301, and Spiromaster PC-10. Its product range supports portable and clinic-based spirometry use cases in Japan and wider Asian markets.

COSMED

COSMED offers the Quark PFT platform with OMNIA software, body plethysmography, respiratory mechanics, airway-resistance, walk-test, and CPET capabilities. Its broad testing portfolio positions the company in specialist laboratories seeking integrated cardiopulmonary and pulmonary diagnostic workflows.

ECO MEDICS

ECO MEDICS is a Swiss manufacturer of the Exhalyzer D system. The platform supports multiple-breath nitrogen washout and lung-clearance-index measurement, with applications in pediatric respiratory assessment, cystic fibrosis, and chronic lung disease monitoring. The Exhalyzer D is an ECO MEDICS product and is not part of MGC Diagnostics' product portfolio.

FUKUDA SANGYO

FUKUDA SANGYO offers respiratory diagnostic products including the ST-190 SpiroAnalyzer and COPD-focused spirometry systems aligned with Japanese respiratory-care requirements. Its regional strength is supported by established domestic medical-device operations and products adapted to Asian clinical practice.

GANSHORN SCHILLER GROUP

GANSHORN SCHILLER GROUP offers the SpiroScout, PowerCube Spiro+, PowerCube Body+, and PowerCube Diffusion+ product families. Its SharpFlow ultrasound technology is a core element of its PFT systems, and the company became part of the SCHILLER Group in 2014. The PowerCube+ Series received FDA 510(k) clearance in 2024.

Geratherm Respiratory

Geratherm Respiratory provides spirometry, body plethysmography, diffusion testing, respiratory-muscle testing, and CPET systems through its BLUE CHERRY diagnostic software platform. Its portfolio includes the Bodystik, PFTstik, Spirostik Blueflow, and related modules for specialist respiratory diagnostics.

medical equipment Europe

medical equipment Europe is a specialist distributor and support provider for pulmonary diagnostic equipment in European clinical markets. Its competitive role is channel access, installation support, and local commercial coverage for manufacturers serving hospitals, respiratory clinics, and diagnostic centers.

Recent Industry Developments

Vitalograph acquisition of Morgan Scientific, September 2024

Vitalograph announced its acquisition of Morgan Scientific on September 23, 2024. The transaction brought Morgan's ComPAS2 pulmonary diagnostic software and U.S. commercial footprint under Vitalograph ownership.

GANSHORN PowerCube+ FDA clearance, 2024

GANSHORN's PowerCube+ Series received FDA 510(k) clearance in 2024. The clearance supports U.S. commercialization of the company's comprehensive PFT platform.

ndd Medical Technologies EasyOne Sky introduction

ndd Medical Technologies introduced EasyOne Sky as a cloud-connected spirometry platform incorporating Buddy coaching, TrueFlow ultrasound measurement, and nddCloud connectivity.